A robust, innovation-driven pipeline is advancing with multiple late-stage and early-stage assets in hematology, oncology, and rare diseases. Key near-term catalysts include pivotal trial readouts in GVHD and IPF, and new clinical programs in myelofibrosis and EGFR-mutant lung cancer, supported by strong financials and strategic collaborations.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.